Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol/Medarex’s Ipilimumab Toxic, But Could Extend Life

This article was originally published in The Pink Sheet Daily

Executive Summary

Melanoma drug’s side effects indicate immune-boosting cancer drug’s effectiveness, investigator tells “The Pink Sheet” DAILY.

You may also be interested in...



Medarex/Bristol Myers Squibbs’ Ipilimumab Shows Off Long-Term Survival Data At ASCO

Data from a separate Phase II combination study also add to hopes for a positive outcome in the ongoing Phase III.

Medarex/Bristol Myers Squibbs’ Ipilimumab Shows Off Long-Term Survival Data At ASCO

Data from a separate Phase II combination study also add to hopes for a positive outcome in the ongoing Phase III.

Medarex/Bristol's Ipilimumab Shows Off Long-Term Survival Data At ASCO

Two-year melanoma survival data from three Phase II studies of Medarex/Bristol-Myers Squibbs' immunotherapeutic ipilimumab presented at the American Society of Clinical Oncology meeting May 31 bode well for an ongoing pivotal Phase III study and an eventual first approval for the oncologic

Related Content

Topics

UsernamePublicRestriction

Register

PS067947

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel